Protective Role of Inhaled Steroids for Covid-19 Infection : Protective Role of Inhaled Steroids for Covid-19 Infection
D1 inclusion / randomization visit:Patients who meet the eligibility criteria and whose infection with Covid-19 has been confirmed within 48 hours will be included in the respiratory diseases department by the pneumologist investigator.Patients will be randomized either to the control group or to the intervention group. For interventional patients, trial treatment (SYMBICORT RAPIHALER 200/6 µ) will begin within 12 hours.Follow-up period (D2 to D29) and end of study visit (D30):Throughout their hospital stay, patients will be followed in accordance with the practice of the service.During hospitalization, investigators are free to decide for antibiotics, steroids, anti viral drugs, hydroxychloroquine and oxygen support management in accordance with local practice. None of the laboratory tests are made for the study. They are usually performed in patients hospitalized for acute respiratory infection.Interventional patient will also be treated with SYMBICORT RAPIHALER 200/6 µg (2 puffs 2 times a day).In the event that the patient is discharged from hospital before the end of his participation, he will be contacted by phone on D30 in order to obtain information concerning the period outside hospitalization.
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
ClinicalTrials.gov - (2021) vom: 03. Aug. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: April 2, 2020, Last downloaded: ClinicalTrials.gov processed this data on August 16, 2021, Last updated: August 18, 2021 |
|---|
| Study ID: |
NCT04331054 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003347885 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003347885 | ||
| 003 | DE-627 | ||
| 005 | 20230426001620.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003347885 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04331054 | ||
| 035 | |a (UBBS_Klinische_Studien)P 200394 | ||
| 035 | |a (UBBS_Klinische_Studien)2020-001306-35 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Protective Role of Inhaled Steroids for Covid-19 Infection |b Protective Role of Inhaled Steroids for Covid-19 Infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: April 2, 2020, Last downloaded: ClinicalTrials.gov processed this data on August 16, 2021, Last updated: August 18, 2021 | ||
| 520 | |a D1 inclusion / randomization visit:Patients who meet the eligibility criteria and whose infection with Covid-19 has been confirmed within 48 hours will be included in the respiratory diseases department by the pneumologist investigator.Patients will be randomized either to the control group or to the intervention group. For interventional patients, trial treatment (SYMBICORT RAPIHALER 200/6 µ) will begin within 12 hours.Follow-up period (D2 to D29) and end of study visit (D30):Throughout their hospital stay, patients will be followed in accordance with the practice of the service.During hospitalization, investigators are free to decide for antibiotics, steroids, anti viral drugs, hydroxychloroquine and oxygen support management in accordance with local practice. None of the laboratory tests are made for the study. They are usually performed in patients hospitalized for acute respiratory infection.Interventional patient will also be treated with SYMBICORT RAPIHALER 200/6 µg (2 puffs 2 times a day).In the event that the patient is discharged from hospital before the end of his participation, he will be contacted by phone on D30 in order to obtain information concerning the period outside hospitalization | ||
| 650 | 2 | |a Infection | |
| 650 | 2 | |a Communicable Diseases | |
| 650 | 2 | |a Respiration Disorders | |
| 650 | 2 | |a Respiratory Tract Diseases | |
| 650 | 4 | |a Medical Condition: Covid-19 Infection, Hospitalization in Respiratory Disease Department | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Terminated | |
| 650 | 4 | |a Phase: Phase 3 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2021) vom: 03. Aug. |
| 773 | 1 | 8 | |g year:2021 |g day:03 |g month:08 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04331054 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 03 |c 08 | ||